Solid-phase synthesis of biologically active fragment 29-111 of rat prothymosin alpha.
Abiko. T T; Sekino. H H
Key Findings
- The 83‑amino‑acid rat prothymosin alpha fragment (29‑111) was successfully synthesized using solid‑phase methods.
- Yield was very low (<1%) but the final peptide was about 96% pure.
- In vitro, the fragment increased E‑rosette‑forming lymphocytes in blood from uremic patients, outperforming synthetic thymosin‑alpha‑1.
Practical Outcomes
- The result suggests the longer prothymosin fragment could be a more potent immune‑boosting agent than thymosin‑alpha‑1, but because it’s a rat peptide, produced in tiny amounts, and only tested ex vivo, there’s no actionable dosage or protocol for human use yet. Biohackers should treat this as preliminary evidence that larger fragments may have benefits, pending further human research.
Summary
Scientists made a long piece of a rat protein (the 29‑111 fragment of prothymosin alpha) in the lab and tested it on blood from kidney‑failure patients. It boosted a type of immune cell more than the shorter thymosin‑alpha‑1 peptide, but the work was done only in test tubes with a rat version and gave a tiny amount of product. So while it hints the bigger fragment might be stronger, it doesn’t provide a clear, safe way for people to use it.
Abstract
Rat prothymosin alpha fragment 29-111, an 83-residue polypeptide corresponding to desthymosin alpha 1-prothymosin alpha, has been synthesized by a solid-phase method. Hydrogen fluoride was used to deprotect and cleave the peptide from the resin. The crude product was purified by gel-filtration, ion-exchange chromatography and high-performance liquid chromatography. A 3.2-mg sample of a ca. 96% pure peptide was finally obtained. The overall yield of the synthesis was less than 1%. An increase of E-rosette-forming lymphocytes was obtained after incubation of peripheral blood from uremic patients with the synthetic prothymosin alpha fragment 29-111. The restoring effect of the synthetic prothymosin alpha fragment 29-111 was greater than that of our synthetic thymosin alpha 1.
Study Information
pubmed
1991